Login to Your Account



Prima Biomed Backpedals After Inconclusive PFS

By Marie Powers
Staff Writer

Thursday, September 19, 2013
Shares of Australia’s Prima Biomed Ltd. were jolted Wednesday after top-line data from the company’s Phase II study of cancer vaccine candidate Cvac showed no observed difference in estimated median progression-free survival (PFS) compared to control in epithelial ovarian cancer patients in first or second remission.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription